JAMA Network June 3, 2024
Ali B. Abbasi, MD; Lesley H. Curtis, PhD; Robert M. Califf, MD

Traditional randomized clinical trials (RCTs) have long been a key tool underpinning drug and device development. The use of individual participant randomization and active or placebo controls in RCTs, combined with comprehensive collection of highly structured data, supports assay sensitivity. At the same time, focused enrollment criteria and careful attention to the collection of adverse events for specified follow-up periods promote detection of toxicities and risks. These...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Clinical Trials, FDA, Govt Agencies, Trends
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article